Home

Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

via GlobeNewswire

CARLSBAD, Calif., March 08, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum, which takes place virtually March 19-20, 2024. John Aballi, Exagen’s President and Chief Executive Officer, and Kamal Adawi, Exagen’s Chief Financial Officer, will participate in one-on-one meetings with investors and a fireside chat on Wednesday, March 20, at 1:30 PM ET.

About Exagen Inc.
Exagen is a leading provider of autoimmune testing and its purpose as an organization is to provide clarity in autoimmune disease decision making with the goal of improving patients’ clinical outcomes. Exagen is located in San Diego County, California.

For more information, please visit Exagen.com or follow @ExagenInc on X (formerly known as Twitter).

Contact:
Ryan Douglas
Exagen Inc.
ir@exagen.com
760.560.1525


Primary Logo

FLOC Investors Have Opportunity to Join Flowco Holdings Fraud Investigation with the Schall Law Firm

via Business Wire

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Flowco Holdings (“Flowco” or “the Company”) (NYSE: FLOC) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Flowco reported its financial results for Q1 2025 on May 13, 2025. The Company missed consensus estimates on revenue and GAAP earnings. The Company claimed that “the U.S. upstream outlook has been challenged by evolving tariff policies, OPEC+ commentary suggesting accelerated production, and broader economic uncertainty.” Based on this news, shares of Flowco fell by more than 12.5% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Contacts